Analysts Set Expectations for VERA Q2 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for shares of Vera Therapeutics in a note issued to investors on Monday, June 2nd. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings of ($0.82) per share for the quarter. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for Vera Therapeutics' Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.85) EPS and FY2025 earnings at ($3.32) EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). During the same period in the previous year, the firm posted ($0.56) earnings per share.

Several other brokerages also recently weighed in on VERA. Cantor Fitzgerald dropped their target price on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Scotiabank boosted their price target on Vera Therapeutics from $55.00 to $65.00 and gave the company a "sector outperform" rating in a research note on Monday. Wedbush dropped their price target on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright boosted their price target on Vera Therapeutics from $75.00 to $85.00 and gave the company a "buy" rating in a research note on Monday. Finally, Guggenheim boosted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $65.00.

Vera Therapeutics Stock Up 3.5%

VERA stock traded up $1.09 on Tuesday, hitting $32.00. 2,516,381 shares of the company's stock were exchanged, compared to its average volume of 867,544. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61. The firm has a 50 day moving average price of $22.15 and a two-hundred day moving average price of $31.86. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a market cap of $2.04 billion, a P/E ratio of -12.26 and a beta of 1.28.

Institutional Trading of Vera Therapeutics

Hedge funds have recently modified their holdings of the stock. Vestal Point Capital LP raised its holdings in Vera Therapeutics by 132.6% in the 1st quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock worth $60,050,000 after purchasing an additional 1,425,000 shares during the period. Avoro Capital Advisors LLC raised its holdings in Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after purchasing an additional 1,300,410 shares during the period. Lord Abbett & CO. LLC raised its holdings in Vera Therapeutics by 170.8% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock worth $48,788,000 after purchasing an additional 727,656 shares during the period. Federated Hermes Inc. raised its holdings in Vera Therapeutics by 162.2% in the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock worth $45,926,000 after purchasing an additional 671,881 shares during the period. Finally, Integral Health Asset Management LLC raised its holdings in Vera Therapeutics by 130.0% in the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock worth $48,634,000 after purchasing an additional 650,000 shares during the period. Hedge funds and other institutional investors own 99.21% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.